Remission of refractory Crohn's disease after autologous hematopoietic stem cell transplantation


Crohn’s disease (CD) is a regional enteritis that affects the terminal ileum, but has the potential of involving any segment of the gastrointestinal tract of the patient.1 The etiology of CD is unknown, but several proven risk factors exist such as family history, smoking, oral contraceptives, diet and ethnicity. The combination of risk factors, and aberrant autoimmune response in the intestinal mucosa with endothelial dysfunction lead to digestive tract malfunctioning. Disease manifestations are heterogeneous but most patients present with abdominal pain, diarrhea sometimes with blood, weight loss, fever and perianal lesions. Up to 30% of CD patients have fistulae. The current treatment is not ideal. Therapy generally involves steroids and anti-tumor necrosis factor alpha (TNF ) blockers but about one-third of patients fail to respond (pri2 mary non-responders) and 10% of patients do not tolerate or are primary non-responders to all drugs used. One-third of responders to anti-TNF treatment show transient loss

DOI: 10.1016/j.bjhh.2015.01.002

Extracted Key Phrases

2 Figures and Tables

Cite this paper

@inproceedings{Ruiz2015RemissionOR, title={Remission of refractory Crohn's disease after autologous hematopoietic stem cell transplantation}, author={Milton Artur Ruiz and Roberto Luiz Kaiser Junior and Mikaell Alexandre Gouv{\^e}a Faria and Luiz Gustavo de Quadros}, booktitle={Revista brasileira de hematologia e hemoterapia}, year={2015} }